47.556560, 7.545484
PDF / print export
Idorsia
Allschwil, Switzerland
- Verified lead
- Martine Clozel
- Lead status
- STATUS: VERIFIED MARCH 2026
- Leadership verification
- Chief Executive Officer
- 2026 technical specialization
- Small-Molecule Discovery, Cardiovascular and Neuroscience Therapeutics, and Clinical Development
- Review cycle
- May 2026
- Full address
- Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
- Site coordinates
- 47.556560, 7.545484
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Official Idorsia Our People page confirming Martine Clozel as CEO.
- Editorial note
- Allschwil R&D headquarters integrating small-molecule discovery, translational pharmacology, and multi-program clinical execution inside the Swiss cluster layer.
Small-Molecule Discovery, Cardiovascular and Neuroscience Therapeutics, and Clinical Development
Clinical-development quality systems, Swiss and EU medicinal-product governance
Allschwil R&D headquarters integrating small-molecule discovery, translational pharmacology, and multi-program clinical execution inside the Swiss cluster layer.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Allschwil, Switzerland
Idorsia
Small-Molecule Discovery, Cardiovascular and Neuroscience Therapeutics, and Clinical Development · Swiss discovery and development headquarters
Allschwil R&D headquarters integrating small-molecule discovery, translational pharmacology, and multi-program clinical execution inside the Swiss cluster layer.
- Lead
- Martine Clozel (verified ↗)
- Address
- Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland (source ↗)
- Compliance
- GLP
- Last reviewed
- 14 Mar 2026 (3mo ago)
- Scale
- Swiss discovery and development headquarters
- Capabilities
- Small-Molecule Discovery · Clinical Development · Translational Pharmacology
- Founded
- 2017
- Headcount
- 501-1000
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED MARCH 2026
Martine Clozel
Chief Executive Officer
Full addressHegenheimermattweg 91, CH-4123 Allschwil, Switzerland
Site coordinates47.556560, 7.545484
Review cycleMay 2026
Physical site source
Official Idorsia contact page listing Hegenheimermattweg 91, Allschwil.
Open sourceSwiss discovery and development headquarters
Allschwil, Switzerland. Small-Molecule Discovery, Cardiovascular and Neuroscience Therapeutics, and Clinical Development. Review completed on 14 Mar 2026.
Swissmedic and EU clinical-development oversight
Clinical-development quality systems, Swiss and EU medicinal-product governance
Small-Molecule Discovery, Cardiovascular and Neuroscience Therapeutics, and Clinical Development
Allschwil R&D headquarters integrating small-molecule discovery, translational pharmacology, and multi-program clinical execution inside the Swiss cluster layer.
Editorial note
Idorsia extends the Swiss discovery layer with a verified 2026 executive record and a clearly disclosed Allschwil physical headquarters site.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleMarch 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Small-Molecule Discovery
Clinical Development
Translational Pharmacology
Cardiovascular and Neuroscience Programs
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Discovery laboratories
Clinical-development systems
Translational research infrastructure
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- VERIFIED ACTIVE 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
14 Mar 2026: Executive identity confirmed via official management disclosure.
14 Mar 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Idorsia located?
- Idorsia operates from Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland, Allschwil, Switzerland.
- Who runs Idorsia?
- Idorsia is led by Martine Clozel, Chief Executive Officer. Verified 14 Mar 2026.
- What does Idorsia do?
- Allschwil R&D headquarters integrating small-molecule discovery, translational pharmacology, and multi-program clinical execution inside the Swiss cluster layer. Core capabilities: Small-Molecule Discovery, Clinical Development, Translational Pharmacology, Cardiovascular and Neuroscience Programs.
Editorial context
Related technical briefs
Briefs that name Allschwil as a covered market or city.